Latest Conference Articles

December 9th 2020, 2:00pm

San Antonio Breast Cancer Symposium

December 9, 2020 - The combination of abemaciclib and standard endocrine therapy showed a 28.7% reduction in the risk of invasive disease recurrence or death compared with endocrine therapy alone in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

December 9th 2020, 1:59pm

ASH Annual Meeting and Exposition

CPX-351, when given at higher doses in induction cycles 1 and 2, significantly prolonged hematologic recovery in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

December 8th 2020, 11:38pm

ASH Annual Meeting and Exposition

Yi Lin, MD, PhD, discusses​s updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

December 8th 2020, 11:33pm

ASH Annual Meeting and Exposition

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

December 8th 2020, 10:24pm

ASH Annual Meeting and Exposition

The antibody-drug conjugate TRPH-222 demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

December 8th 2020, 9:37pm

ASH Annual Meeting and Exposition

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.

December 8th 2020, 6:16pm

ASH Annual Meeting and Exposition

Results reported from a group of patients with heavily pretreated multiple myeloma who were administered the combination of selinexor plus pomalidomide and low-dose dexamethasone produced positive responses and provided rationale for further investigation into the regimen.

December 8th 2020, 6:00pm

ASH Annual Meeting and Exposition

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

December 8th 2020, 5:37pm

ASH Annual Meeting and Exposition

December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.

December 8th 2020, 3:00pm

ASH Annual Meeting and Exposition

JAK2 and DNMT3A driver mutations can be acquired as early as in utero in patients with myeloproliferative neoplasms, demonstrating variable rates of clonal expansion and growth that influence the time to diagnosis.

December 8th 2020, 3:00pm

ASH Annual Meeting and Exposition

Asciminib demonstrated a statistically significant and clinically meaningful improvement in the major molecular response rate at 24 weeks compared with bosutinib in patients with chronic myeloid leukemia in chronic phase who have received at least 2 prior TKIs.

December 8th 2020, 2:50pm

ASH Annual Meeting and Exposition

December 8, 2020 - Fixed-duration treatment with mosunetuzumab elicited high, durable, and consistent responses across numerous subgroups of patients with follicular lymphoma.

December 8th 2020, 1:54pm

ASH Annual Meeting and Exposition

December 8, 2020 - The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

December 8th 2020, 1:02pm

ASH Annual Meeting and Exposition

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

December 8th 2020, 3:00am

ASH Annual Meeting and Exposition

LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 8th 2020, 1:25am

ASH Annual Meeting and Exposition

December 7, 2020 - Ponatinib resulted in high response rates and robust survival outcomes in patients with chronic-phase chronic myeloid leukemia who have progressed on previous treatment with a second-generation TKI.

December 8th 2020, 12:50am

ASH Annual Meeting and Exposition

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

December 7th 2020, 11:15pm

ASH Annual Meeting and Exposition

Christian Buske, MD, discusses ​the results of the iNNOVATE trial in Waldenström macroglobulinemia.

December 7th 2020, 11:15pm

ASH Annual Meeting and Exposition

December 7, 2020 - The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to improved hematologic complete response rate compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.

December 7th 2020, 10:31pm

ASH Annual Meeting and Exposition

Panobinostat, given at a 20-mg 3-times-weekly or twice-weekly dosing schedule, in combination with subcutaneous bortezomib and dexamethasone showed durable responses and an acceptable safety profile in patients with relapsed or relapsed/refractory myeloma.